摘要
目的:评价参麦注射液辅助治疗慢性充血性心力衰竭(congestive heart failure,CHF)的临床疗效,并探讨其对患者血清超敏C反应蛋白(high-sensitivity C-reactive protein,hsCRP)及脑钠肽(brain natriuretic peptide,BNP)水平的影响。方法:选择心功能II^IV级(NYHA)的CHF患者120例,随机分为对照组和治疗组(每组60例),两组患者均予常规治疗,治疗组在常规治疗基础上静滴参麦注射液,两组均治疗15天,检测和比较两组治疗前后患者的血清hsCRP、BNP水平和心脏超声测定左心室射血分数(LVEF)及左心室舒张末期内径(LVEDd)。结果:对照组和治疗组的心功能临床有效率分别为73.7%和88.7%,治疗组显著高于对照组(P<0.05)。治疗后,两组LVEF均较治疗前明显升高(P<0.05),LVEDd均较治疗前明显缩小(P<0.05),且治疗组与对照组相比有统计学差异(P<0.05)。而治疗后,两组血浆BNP和hsCRP水平均较治疗前显著下降(P<0.01),且治疗组显著低于对照组(P<0.05)。两组治疗过程中均无明显不良反应发生。结论:参麦注射液辅助治疗CHF的疗效较常规治疗更好,可显著降低患者血清hsCRP、BNP水平,改善左室功能。
Objective： To evaluate the clinical efficacy of shenmai injection and investigate its effect on the serum levels of high-sensitivity C-reactive protein（hsCRP） and brain natriuretic peptide（BNP）.in the adjunctive treatment of patients with chronic congestive heart failure.Methods： 120 patients with CHF,which NYHA II^IV,enrolled in the study.All the patients were randomly divided into the Shenmai injecta treatment group（60 cases） and control group（60 cases）.The serum levels of hsCRP and BNP were evaluated,and the left ventricular ejection function（LVEF） as well as left ventricular end-diastolic diameter（LVEDd） were detected with cardiography before and 2 weeks after treatment.Results： After treatment,the total effective rates of the control group and treatment group were respectively 73.7% and 88.7%,which was significantly higher in the treatment group（P0.05）,the LVEF were increased obviously while the LVEDd were decreased significantly after treatment in both groups（P0.05）,and significant differences were found between two groups（P0.05）.The level of plasma BNP decreased in both two groups after treatment（P0.01）,although the treatment group was more significant than control group（P0.05）.Conclusion： It was demonstrated that the clincial efficacy of Shenmai injection was superior to the conventional treatment in the adjunctive treatment of patients with chronic congestive heart failure,and Shenmai injection could significantly decrease the serum levels of hsCRP and BNP.
出处
《现代生物医学进展》
CAS
2013年第13期2550-2553,2561,共5页
Progress in Modern Biomedicine
关键词
参麦注射液
心力衰竭
超敏C反应蛋白
脑钠肽
临床疗效
Shenmai injection
Congestive heart failure
HsCRP
Brain netriuretic peptide
Clinical efficacy
